The AHSN Network has been announced as a Founding Collaborator of The Sustainable Medicines Partnership (SMP), a not-for-profit, global collaboration which undertakes projects to make the use of medicines more sustainable and less wasteful.

The partnership includes leading pharma, generic and retail medicines manufacturers, distributors, supply chain, technology providers, healthcare, hospitals, pharmacy, researchers, academia, policymakers and changemakers.

Pete Waddingham, Net Zero Lead at The AHSN Network, said:

“We are delighted to be part of the Sustainable Medicine Partnership. There are a number of reasons why we wanted to part of this partnership. Firstly, the AHSN Network are actively involved in both national and local programmes which impact on patients and the medicines they take.

“The AHSN Network works with innovators that can directly contribute to better medicine use and also support the NHS supply chain. These range from organisations that help improve patient communication and understanding of their care, keeping people at home and monitored, through to innovation that can help the supply chain reduce its energy use or improve their logistics.

“Finally, we will only be able to tackle this climate emergency if we work in collaboration with others. The SMP gives us this opportunity, on the subject of medicines, along with some great partnership organisations.

“I am particularly looking forward to exploring what opportunities the SMP can bring to enhancing a number of our national programmes including polypharmacy or lipid management.”

Through a four year programme of priority actions, the Sustainable Medicines Partnership aims to reduce the waste of medicines and from medicines – reducing healthcare emissions and increasing health equity globally.

AHSNs support the NHS to deliver its Net Zero commitments through identifying new products, technologies and ways of working to support this agenda. To do this, we have developed our AHSN Network Environmental Sustainability Strategy.

The Network’s Polypharmacy Programme aims to increased confidence amongst primary care prescribing workforce and patients in order to safely stop medicines identified to be inappropriate or unnecessary, Studies have shown that that over 50% of older people are prescribed a medicine with more harm than benefit. In England there were more than 800k people on 10 or more medicines and these are 300% more likely to be admitted to hospital.

The national lipids optimisation programme aims to improve the management of cholesterol, increase the detection of those with Familial Hypercholesterolaemia and optimise the use of all medicines for patients.

Pete continued: “As set out in a recent report, overprescribing medication results in millions of packets of medicine wasted each year, which consumes energy, plastics and other resources… the production and use of some medicines can generate significant greenhouse gas emissions and so contribute to climate change. Reducing [this] will help the NHS fulfil its commitment to become carbon net zero.

Alanguage is not English, people with lower levels of health literacy, accessibility issues, or people just wanting simple, easy to understand information on their medication can all benefit if we work in collaboration with innovators, patients and industry.”

Find out more about the SMP at



  • Until tackling health inequalities becomes business as usual, innovation is our best chance of equity

    Dr Stuart Monk, National Programme Director for the Accelerated Access Collaborative (AAC) Programmes at the Health Innovation Network, talks about the pivotal role of innovation tackling healthcare inequalities in the NHS. At the Royal Society of Medicine’s Tackling Inequalities conference it was clear from the passion in the room that great progress has been made [...]

  • Where health innovation is concerned, 15 approaches are better than one

    Dr Phil Jennings, Vice Chair of the Health Innovation Network and Chief Executive of Health Innovation North West Coast, discusses why the Network’s collective relicensing gives innovation a better chance of success. In any one day in England, 1.2 million people attend a GP appointment, over a quarter of a million people have an outpatient [...]

  • Meet the innovator: Damian O’Boyle,

    Kidney care costs the NHS £1.5bn a year. Minuteful Kidney, from, is a home kidney albumin to creatinine ratio (ACR) test. It identifies more patients at-risk of chronic kidney disease (CKD) and associated cardiovascular disease (CVD), which is a leading cause of morbidity, disability and health inequalities. Damian O’Boyle, Director of Client Services at [...]